ISPN
Visitors
76076
September
24
Journals A - Z
A   B   C   D   E   F   G   H   I   J   K   L   M   N   O   P   Q   R   S   T   U   V   W   X   Y   Z    ALL
All Volumes

Build-up Caps to be Used in In-vivo Thermoluminescence Dosimetry

How to cite

Dr.Abdelmoneim Adam Mohamed Sulieman,K . Theodorou ,C . Kappas ,J. Kalef- Ezra ,2011, Build-up Caps to be Used in In-vivo Thermoluminescence Dosimetry,Journal of Science and Technology,12 (1) ,pp:1-3

Authors:
By Dr.Abdelmoneim Adam Mohamed Sulieman,K . Theodorou ,C . Kappas ,J. Kalef- Ezra ,
Year:
2011
Keywords
TLD, Radiation therapy, Thermoluminescence
Abstract
Thermoluminescence dosimeters (TLDs) are widely used for quality assurance in radiation therapy. To avoid steep dose gradients, such measurements are usually made at either the depth of maximum dose Dmax or at the exit skin surface, to assess in vivo the entrance and exit doses respectively. The build-up caps to be used have, among others, to induce minimal perturbation to the treatment field and the registered dose to be as close as possible to that to be assessed in order to reduce the size of the possible errors of the measurement. The aim of the present study was to assess the influence on the TL signal of the geometrical characteristics of cylindrical caps made of various materials at various photon fields. Cylindrical caps of various sizes made of plexiglas, aluminum, copper and stainless steel were constructed to accommodate four 3.1x3.1x0.9 mm LiF: Mg, Ti TLDs per cap. The relationships between the doses registered by the TLDs and the entrance and exit doses measured in phantoms with ionization chambers in 6 and 15 MV fields, were determined. The deviations from the dose registered by the TLDs and those measured by ionization chambers, increased with increasing material density. The ratio of the measured dose to the expected dose was equal to 2.5%. The signal increased with build-up cap atomic number. On the other hand, build-up caps made up of Cu were found to be optimum for high-energy photon fields and caps made up of Plexiglas for low energy fields.
ÇáăáÎŐ
References:
  1. Lapidus H, Lordi G. N., (1999). Drug release from compressed hydophyllic matrices. J Pharm Sci. 57:1292-1301
  2. Mockel J. E., Lippold B. C., (2003). Zero-order drug release from hydrocolloid matrices. Pharm Res.90:1066-1070
  3. Kim C. J., (1999). Drug release form compressed hydrophillic POLYOXWSR tablets. J Pharm Sci.84:303-306
  4. Lee PI, Peppas N. A., (1999). Prediction of polymer dissolution in swellable controlled-release systems. J Control Rel.6:207-215
  5. Bumphrey G, (1999). ‘Extremely useful’ new suspending agent. Pharm J.237:665-671
  6. Lu M. F., Woodward L, Borodkin S., (2000).Xanthan gum and alginate based controlled release theophylline formulations. Drug Dev Ind Pharm.17:987-991
  7. Talukdar M. M., Plaizier-Vercammen J, (2004). Evaluation of xanthan gum as a hydrophillic matrix for controlled release dosage form preparations. Drug Dev Ind Pharm.19:1037-1046
  8. Tobyn M. J., Staniforth J. N., Baichwal A. R., McCall T. W., (1999). Prediction of physical properties of a novel polysaccharide controlled release system. Int. J. Pharm.128: 113-122
  9. Nochodchi, A., Farid, D. J., Najdfi, M. and Adrangui, M. (1997). Drug Develop. Ind. Pharm.23, 1019
  10. Lachman, L., Liberman, H.A. and Kanig, J. L. (2004). In; The Theory and Practice of Industrial Pharmacy, 3rd Edn., Varghese Publishing House, Mumbai, ,85
  11. Farid, D., Adrangui, M. R. and Saeedi, M., (2004). Development and characterization of matrix tablets of Diltiazim, Pharmazie. 56: 223-226
  12. Andreopoulos, A. G. and Tarantili, P.A., J. (2005). Biomed. Appl.60: 116- 119
  13. Craig, D. Q .M., (1990). Drug Development Industrial Pharmacy, 16, 2501
  14. M. M. and Plaizer-verammen, J., Drug Develop, (2003). Ind. Pharm., 19, 1042
  15. Kanig J .L., (2001). In; The Theory and Practice of Industrial Pharmacy, 3rd Edn., Varghese Publishing House, Mumbai, 88. 45
  16. Reynolds J. E. F., Eds., (2006). In; Martindale: The Extra Pharmacopoeia, 31st Edn., The Pharmaceutical Press, London,
  17. Gwen M. J. and Joseph, R. R., In; Banker, G. S. and Rhodes, C.T., Eds., (2006). Modern Pharmaceutics, 3r Edn., . 72,158-166 Marcel Dekker, Inc., New York,
  18. Talukdar V., O'Keeffe, J.C. and Horton, M., Drug Develop, (2004). Ind. Pharm., 7:20-25
  19. Swarbrick J. (2006). Advances in controlled drug delivery. S. T. P. Pharma.6:53-56
  20. Mishra B., Seena, J., Singh S., Sankar, C, (2003). Development and characterization of matrix tablets of ketorolac tromethamine. Indian Pharm. 2:86-89
  21. Chirico S, Dalmoro A, Lamberti G, Russo G, Titomanlio G, (2007). Analysis and modeling of swelling and erosion behavior for pure HPMC tablet. J.Pharm.Sci;122:181-188
  22. Vazquez M. J., Casalderrey M, Concheiro A, (2006). Atenolol release from hydrophilic matrix tablets with hydroxypropylmethylcellulose (HPMC) mixtures as gelling agent: effects of the viscosity of HTML mixture. Eur.J.Pharm.Sci.4:39-48
  23. Efentakis M., (1997) .Effects of excipients on swelling and drug release from compressed matrices. Drug Development and Industrial Pharmacy, 23 (1):107-112
  24. Sankar C. (2001). Chitosan based pentazocine microspheres for intranasal systemic delivery– development and biopharmaceutical evaluation. Pharmazie.56: 223-2
  25. Sankar C., Rani, M., Srivastava, A.K., Mishra, B, (2001). Chitosan based pentazocine microspheres for intranasal systemic delivery– development and biopharmaceutical evaluation. Pharmazie. 56: 223-226
  26. Agarwal V., Mishra, B, (2007). Design, development and biopharmaceutical properties of buccoadhesive compacts of pentazocine. Drug. Dev. Ind. Pharm. 25:701-709
  27. Lucy W. S. C., Paul, W. S. H., Wong, F. L, (2006). Relationship between polymer viscosity and drug release from a matrix system. Pharm. Res. 9:1510-1512
» Download Full Text: